Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report.

José Ramón SantosAna MerinoWalter E HaefeliCristina MirandaMarisol PratsIoana BancuLucía BailónJosé Moltó

Published in: BMC nephrology (2020)

Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.

Keyphrases

end stage renal disease
peritoneal dialysis
chronic kidney disease
hiv infected
pulmonary hypertension
patients undergoing
antiretroviral therapy
case report
pulmonary arterial hypertension